Quest Diagnostics Q1 2024 10-Q Filed
Ticker: DGX · Form: 10-Q · Filed: 2024-04-24T00:00:00.000Z
Sentiment: neutral
Topics: 10-Q, financials, quarterly-report
TL;DR
Quest Diagnostics filed its Q1 2024 10-Q. Financials are in.
AI Summary
Quest Diagnostics Inc. filed its 10-Q for the period ending March 31, 2024. The filing details the company's financial performance and position as of that date. Key financial statements and disclosures are included, providing insights into the company's operations and any material changes since the last filing.
Why It Matters
This filing provides investors and analysts with the latest financial data for Quest Diagnostics, crucial for understanding the company's performance and making informed investment decisions.
Risk Assessment
Risk Level: low — This is a routine quarterly financial filing and does not inherently present new risks.
Key Numbers
- N/A — Revenue (Specific revenue figures for the quarter are not detailed in the provided header information.)
- N/A — Net Income (Specific net income figures for the quarter are not detailed in the provided header information.)
- N/A — Earnings Per Share (Specific EPS figures for the quarter are not detailed in the provided header information.)
Key Players & Entities
- QUEST DIAGNOSTICS INC (company) — Filer
- 20240331 (date) — Period of Report
- 20240424 (date) — Filing Date
- SECAUCUS, NJ (location) — Business Address
FAQ
What were Quest Diagnostics' total revenues for the first quarter of 2024?
The provided header information does not contain specific revenue figures for the first quarter of 2024.
What was Quest Diagnostics' net income for the period ending March 31, 2024?
Specific net income details for the period ending March 31, 2024, are not present in the header information.
Did Quest Diagnostics announce any significant acquisitions or divestitures in this filing?
The provided header information does not mention any acquisitions or divestitures.
What is the company's current cash position as of March 31, 2024?
The header information does not provide specific details on the company's cash position.
Are there any updates on ongoing litigation or regulatory matters mentioned in this 10-Q?
The header information does not include details on litigation or regulatory matters.
From the Filing
0001022079-24-000099.txt : 20240424 0001022079-24-000099.hdr.sgml : 20240424 20240424161222 ACCESSION NUMBER: 0001022079-24-000099 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 64 CONFORMED PERIOD OF REPORT: 20240331 FILED AS OF DATE: 20240424 DATE AS OF CHANGE: 20240424 FILER: COMPANY DATA: COMPANY CONFORMED NAME: QUEST DIAGNOSTICS INC CENTRAL INDEX KEY: 0001022079 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 161387862 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-12215 FILM NUMBER: 24870711 BUSINESS ADDRESS: STREET 1: 500 PLAZA DRIVE CITY: SECAUCUS STATE: NJ ZIP: 07094 BUSINESS PHONE: 9735202700 MAIL ADDRESS: STREET 1: 500 PLAZA DRIVE CITY: SECAUCUS STATE: NJ ZIP: 07094 FORMER COMPANY: FORMER CONFORMED NAME: CORNING CLINICAL LABORATORIES INC DATE OF NAME CHANGE: 19960903 10-Q 1 dgx-20240331.htm 10-Q dgx-20240331 0001022079 12/31 2024 Q1 FALSE 0001022079 2024-01-01 2024-03-31 0001022079 2024-04-15 xbrli:shares iso4217:USD 0001022079 2023-01-01 2023-03-31 iso4217:USD xbrli:shares 0001022079 2024-03-31 0001022079 2023-12-31 0001022079 2022-12-31 0001022079 2023-03-31 0001022079 us-gaap:CommonStockMember 2023-12-31 0001022079 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001022079 us-gaap:RetainedEarningsMember 2023-12-31 0001022079 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001022079 us-gaap:TreasuryStockCommonMember 2023-12-31 0001022079 us-gaap:NoncontrollingInterestMember 2023-12-31 0001022079 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001022079 us-gaap:NoncontrollingInterestMember 2024-01-01 2024-03-31 0001022079 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0001022079 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001022079 us-gaap:TreasuryStockCommonMember 2024-01-01 2024-03-31 0001022079 us-gaap:CommonStockMember 2024-03-31 0001022079 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001022079 us-gaap:RetainedEarningsMember 2024-03-31 0001022079 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001022079 us-gaap:TreasuryStockCommonMember 2024-03-31 0001022079 us-gaap:NoncontrollingInterestMember 2024-03-31 0001022079 us-gaap:CommonStockMember 2022-12-31 0001022079 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001022079 us-gaap:RetainedEarningsMember 2022-12-31 0001022079 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001022079 us-gaap:TreasuryStockCommonMember 2022-12-31 0001022079 us-gaap:NoncontrollingInterestMember 2022-12-31 0001022079 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001022079 us-gaap:NoncontrollingInterestMember 2023-01-01 2023-03-31 0001022079 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0001022079 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001022079 us-gaap:TreasuryStockCommonMember 2023-01-01 2023-03-31 0001022079 us-gaap:CommonStockMember 2023-03-31 0001022079 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001022079 us-gaap:RetainedEarningsMember 2023-03-31 0001022079 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001022079 us-gaap:TreasuryStockCommonMember 2023-03-31 0001022079 us-gaap:NoncontrollingInterestMember 2023-03-31 0001022079 dgx:InvigorateProgramMember 2024-03-31 xbrli:pure 0001022079 dgx:InvigorateProgramMember 2024-01-01 2024-03-31 0001022079 dgx:InvigorateProgramMember 2023-01-01 2023-03-31 0001022079 us-gaap:CostOfSalesMember dgx:InvigorateProgramMember 2024-01-01 2024-03-31 0001022079 us-gaap:SellingGeneralAndAdministrativeExpensesMember dgx:InvigorateProgramMember 2024-01-01 2024-03-31 0001022079 us-gaap:CostOfSalesMember dgx:InvigorateProgramMember 2023-01-01 2023-03-31 0001022079 us-gaap:SellingGeneralAndAdministrativeExpensesMember dgx:InvigorateProgramMember 2023-01-01 2023-03-31 0001022079 us-gaap:AccountsPayableAndAccruedLia